BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 10827226)

  • 1. Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective, randomized, controlled clinical trial.
    Mitzner SR; Stange J; Klammt S; Risler T; Erley CM; Bader BD; Berger ED; Lauchart W; Peszynski P; Freytag J; Hickstein H; Loock J; Löhr JM; Liebe S; Emmrich J; Korten G; Schmidt R
    Liver Transpl; 2000 May; 6(3):277-86. PubMed ID: 10827226
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Efficiency of dialysis with albumin in the treatment of patients with advanced hepatic insufficiency: initial experience with the MARS system in Spain].
    Avilés J; Macía M; Morales S; Pérez F; Moreno A; Navarro J; Navazo L; García J
    Nefrologia; 2001; 21(4):376-85. PubMed ID: 11816514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular adsorbent recirculating system is ineffective in the management of type 1 hepatorenal syndrome in patients with cirrhosis with ascites who have failed vasoconstrictor treatment.
    Wong F; Raina N; Richardson R
    Gut; 2010 Mar; 59(3):381-6. PubMed ID: 19710033
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extracorporeal detoxification using the molecular adsorbent recirculating system for critically ill patients with liver failure.
    Mitzner SR; Stange J; Klammt S; Peszynski P; Schmidt R; Nöldge-Schomburg G
    J Am Soc Nephrol; 2001 Feb; 12 Suppl 17():S75-82. PubMed ID: 11251037
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Type-2 hepatorenal syndrome and refractory ascites: role of transjugular intrahepatic portosystemic stent-shunt in eighteen patients with advanced cirrhosis awaiting orthotopic liver transplantation.
    Testino G; Ferro C; Sumberaz A; Messa P; Morelli N; Guadagni B; Ardizzone G; Valente U
    Hepatogastroenterology; 2003; 50(54):1753-5. PubMed ID: 14696397
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome.
    Wong F; Pantea L; Sniderman K
    Hepatology; 2004 Jul; 40(1):55-64. PubMed ID: 15239086
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modification of continuous venovenous hemodiafiltration with single-pass albumin dialysate allows for removal of serum bilirubin.
    Chawla LS; Georgescu F; Abell B; Seneff MG; Kimmel PL
    Am J Kidney Dis; 2005 Mar; 45(3):e51-6. PubMed ID: 15754264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular adsorbent recirculating system (Mars) in patients with primary nonfunction and other causes of graft dysfunction after liver transplantation in the era of extended criteria donor organs.
    Gaspari R; Cavaliere F; Sollazzi L; Perilli V; Melchionda I; Agnes S; Gasbarrini A; Avolio AW
    Transplant Proc; 2009; 41(1):253-8. PubMed ID: 19249528
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First use of the Molecular Adsorbent Recirculating System technique on patients with hypoxic liver failure after cardiogenic shock.
    El Banayosy A; Kizner L; Schueler V; Bergmeier S; Cobaugh D; Koerfer R
    ASAIO J; 2004; 50(4):332-7. PubMed ID: 15307543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study.
    Ortega R; Ginès P; Uriz J; Cárdenas A; Calahorra B; De Las Heras D; Guevara M; Bataller R; Jiménez W; Arroyo V; Rodés J
    Hepatology; 2002 Oct; 36(4 Pt 1):941-8. PubMed ID: 12297842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study.
    Martín-Llahí M; Pépin MN; Guevara M; Díaz F; Torre A; Monescillo A; Soriano G; Terra C; Fábrega E; Arroyo V; Rodés J; Ginès P;
    Gastroenterology; 2008 May; 134(5):1352-9. PubMed ID: 18471512
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liver support by extracorporeal blood purification: a clinical observation.
    Stange J; Mitzner SR; Klammt S; Freytag J; Peszynski P; Loock J; Hickstein H; Korten G; Schmidt R; Hentschel J; Schulz M; Löhr M; Liebe S; Schareck W; Hopt UT
    Liver Transpl; 2000 Sep; 6(5):603-13. PubMed ID: 10980060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Albumin dialysis in cirrhosis with superimposed acute liver injury: a prospective, controlled study.
    Heemann U; Treichel U; Loock J; Philipp T; Gerken G; Malago M; Klammt S; Loehr M; Liebe S; Mitzner S; Schmidt R; Stange J
    Hepatology; 2002 Oct; 36(4 Pt 1):949-58. PubMed ID: 12297843
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The management of hepatorenal syndrome.
    Carl DE; Sanyal A
    Minerva Gastroenterol Dietol; 2009 Jun; 55(2):207-26. PubMed ID: 19305378
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of hepatorenal syndrome as defined by the international ascites club by albumin and furosemide infusion according to the central venous pressure: a prospective pilot study.
    Péron JM; Bureau C; Gonzalez L; Garcia-Ricard F; de Soyres O; Dupuis E; Alric L; Pourrat J; Vinel JP
    Am J Gastroenterol; 2005 Dec; 100(12):2702-7. PubMed ID: 16393223
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of the molecular adsorbent recirculating system and Prometheus devices on systemic haemodynamics and vasoactive agents in patients with acute-on-chronic alcoholic liver failure.
    Laleman W; Wilmer A; Evenepoel P; Elst IV; Zeegers M; Zaman Z; Verslype C; Fevery J; Nevens F
    Crit Care; 2006; 10(4):R108. PubMed ID: 16859530
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Hepatorenal syndrome].
    Radziszewski A; Sułowicz W
    Przegl Lek; 2006; 63(7):573-8. PubMed ID: 17203812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination treatment with octreotide, midodrine, and albumin improves survival in patients with type 1 and type 2 hepatorenal syndrome.
    Skagen C; Einstein M; Lucey MR; Said A
    J Clin Gastroenterol; 2009 Aug; 43(7):680-5. PubMed ID: 19238094
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute-on-chronic liver failure: the RELIEF trial.
    Bañares R; Nevens F; Larsen FS; Jalan R; Albillos A; Dollinger M; Saliba F; Sauerbruch T; Klammt S; Ockenga J; Pares A; Wendon J; Brünnler T; Kramer L; Mathurin P; de la Mata M; Gasbarrini A; Müllhaupt B; Wilmer A; Laleman W; Eefsen M; Sen S; Zipprich A; Tenorio T; Pavesi M; Schmidt HH; Mitzner S; Williams R; Arroyo V;
    Hepatology; 2013 Mar; 57(3):1153-62. PubMed ID: 23213075
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Albumin dialysis (MARS therapy) in patients with hepatic graft dysfunction].
    Aleksandrova IV; Ermolov AS; Chzhao AV; Artamonov VV; Reĭ SI
    Anesteziol Reanimatol; 2008; (6):67-70. PubMed ID: 19227298
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.